Effects of losartan on renal function in patients with essential hypertension

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 2, 1996, Pages 259-263

  Fauvel, J P ^a   Velon, S ^a   Berra, N ^a   Pozet, N ^a   Madonna, O ^a   Zech, P ^a   Laville, M ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Hypertension; Lithium clearance; Losartan; Microalbuminuria; Renal function; Uric acid

Indexed keywords

LOSARTAN; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SODIUM ABSORPTION; SODIUM EXCRETION;

ALBUMINURIA; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; KIDNEY; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENAL CIRCULATION; SINGLE-BLIND METHOD; SODIUM; TETRAZOLES; URIC ACID;

EID: 0029744536     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199608000-00012     Document Type: Article

References (38)

1. Lewis EJ, Hunsicker GL, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
2. Kamper AL, Strandgaard S, Leyssac PP. Late outcome of controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995;10:1182-8.
3. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and β-blockers in non diabetic chronic renal failure. Br Med J 1994;309:833-7.
4. Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of non diabetic chronic renal disease. Arch Intern Med 1993;153:1749-59.
5. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995:155:1073-80.
6. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 1992;6:108-13.
7. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptor. Hypertension 1991;17:720-1.
8. Murphy TJ, Alexender RW, Grindling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type 1 angiotensin 2 receptor. Nature 1991;351:233-6.
9. Sasaki K, Yamano Y, Bardhan S. et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin 2 type 1 receptor. Nature 1991;351:230-2.
10. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. J Biol Chem 1993;268:24539-42.
11. Kambayashi Y. Bardhan S. Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993;268:24543-6.
12. Clark KL, Robertson MJ, Drew GM. Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anesthetized dog. Br J Pharmacol 1993; 109:148-56.
13. Timmermans PB, Chiu AT, Herblin WE, Wong PC, Smith RD. Angiotensin 2 receptor subtypes. Am J Hypertens 1992; 5:406-10.
14. Secchi LA, Gradi EF. Griffin CA, Kalinyac JE, Schambelan M. Distribution of angiotensin 2 receptor subtypes in rat and human kidney. Am J Physiol 1992;262:236-40.
15. Gansevoort RT. De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
16. Erley CM. Bader B, Scheu M, Wolf S, Braun N, Risler T. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol 1995;43(suppl 1):S8-11
17. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-7.
18. Galli A, Jeanmaire J. Dosage colorimétrique de l'inuline dans le sang et dans les urines. Application à l'analyse automatique. Ann Biol Clin 1965;23:931-41.
19. Bratton AC, Marshall EK. A new coupling component for sulfanilamide determination. J Biol Chem 1939;128:537-44.
20. Thomsen K. Lithium clearance. A new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984;37:217-23.
21. Lo M, Liu KL, Lantelme P, Sassard J. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995;95:1394-7.
22. Weber MA. Clinical experience with the angiotensin 2 receptor antagonist losartan. A preliminary report. Am J Hypenens 1992;5:S247-51.
23. Bovee KC, Wong PC, Timmermans PB, Thoolen MJ. Effects of the nonpeptide angiotensin 2 receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 1991;4:S327-33.
24. Chan DP, Sandok EK, Aarhus LL, Heblein DM, Burnett JC. Renal-specific actions of antagonist 2 receptor antagonism in the anesthetized dog. Am J Hypertens 1992;5:354-60.
25. El-Amrani AI, Menard J, Gonzales ME, Michel JB. Effects of blocking the angiotensin 2 receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol 1993;22:231-9.
26. Fenoy FJ, Milicic I, Smith RD, Wong PC, Timmermans PB, Roman R. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens 1991;4:S321-6.
27. Keiser JA, Bjork FA, Hodges JC, Taylor DG. Renal hemodynamic and excretory responses to PD 123319 and losartan nonpeptide AT1 and AT2 subtype-specific angiotensin 2 ligands. J Pharmacol Exp Ther 1992;262:1154-60.
28. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW. Effects of angiotensin 2 receptor blockade on remnant glomerular permselectivity. Kidney Int 1993;43:346-53.
29. Tamaki-T, Nishiyama-A, Yoshida-H, He-H, Fukui-T, Yamamoto-A, Aki-H, Kimura-S, Iwao-H, Miyakate-A. Effects of EXP3174, a non peptide angiotensin 2 receptor antagonist, on renal hemodynamics and renal function in dogs. Eur J Pharmacol 1993;236:15-21.
30. Hajj-ali AF, Zimmerman BG. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 1991;17:504-9.
31. Fenoy JF, Scicli G, Carretero O, Roman RJ. Effect of an angiotensin 2 and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991;17: 1038-14.
32. Bauer JH, Reams GP, Wu Z, Lau-Sieckman A. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995;9:237-43.
33. Hutchinson FN, Webster SK. Effect of ANG II receptor antagonist on ambuminuria and renal function in passive Heymann nephritis. Am J Physiol 1992;263:311-8.
34. Cogan MG, Xie MH, Liu FY, Wong PC, Timmermans PB. Effects of DuP 753 on proximal nephron and renal transport. Am J Hypertens 1991;4:S315-20.
35. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.
36. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antag onist losartan (Dup 753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993;21:732-8.
37. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of Dup-753, a new angiotensin 2 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-5.
38. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.